NASDAQ
FLNA
Last Price
US $1.19
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Filana Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.
Financial risk - Healthy cash flow growth.
Filana Therapeutics, Inc. has insufficient data to evaluate this check.
Financial risk - Healthy debt to equity ratio.
Filana Therapeutics, Inc. has insufficient data to evaluate this check.
Financial risk - Healthy debt to equity ratio development.
Filana Therapeutics, Inc. has insufficient data to evaluate this check.
Financial risk - Net debt/EBITDA.
Filana Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Filana Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Filana Therapeutics, Inc. has insufficient data to evaluate this check.
Financial risk - Short term assets vs short term liabilities.
Filana Therapeutics, Inc. has insufficient data to evaluate this check.
Decreasing performance - ROA.
Filana Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Filana Therapeutics, Inc.'s return on equity of -99.85%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Filana Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Filana Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Filana Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Filana Therapeutics, Inc. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Filana Therapeutics, Inc.'s yearly earnings has decreased 273.73% since last year from $-24.34M to $-90.97M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Filana Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Decreasing performance - ROIC.
ROIC -120.10% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Filana Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Filana Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Filana Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Filana Therapeutics, Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Filana Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Filana Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Filana Therapeutics, Inc. has an EV/EBITDA ratio of 0.37x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Filana Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Filana Therapeutics, Inc. has a price-to-book ratio of 0.85x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Filana Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-99.85%
Return on equity
ROIC: -120.10%
Valuation History
-0.75X
Price to Earnings
EV/EBITDA: 0.37X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $1.19
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.